Following Kyowa Kirin International and NewBridge Pharmaceuticals?
Get the free weekly contract digest
The latest new contracts, like Kyowa Kirin International and NewBridge Pharmaceuticals’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa
Aug 07, 2024•almost 2 years ago
Contract Type
agreement
Mount Lebanon GovernorateBiotechnologyHealth CarePharmaceutical
Description
Kyowa Kirin International (KKI) and NewBridge Pharmaceuticals have signed a Promotion and Distribution Agreement to distribute KKI's existing rare disease portfolio, including CRYSVITA® and POTELIGEO®, across the Middle East and North Africa. NewBridge will exclusively distribute the two products in several MENA countries and aims to support disease awareness, improve time to diagnosis, and enhance access to innovative treatments for rare and orphan diseases.
Company Information
Company
Kyowa Kirin International and NewBridge Pharmaceuticals
Location
Mount Lebanon Governorate, Lebanon
About
Kyowa Kirin International and NewBridge Pharmaceuticals have entered into an agreement to improve access to medicines for rare disease patients across the Middle East and North Africa.
Predictive Intelligence
Strategic
ML-powered predictions for Kyowa Kirin International and NewBridge Pharmaceuticals's next move
Mount Lebanon GovernorateBiotechnologyHealth CarePharmaceutical